Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma

Clinical Cancer Research

Volumn 19, Issue 8, 2013, Pages 2257-2264

  Catalanotti, Federica ^a   Solit, David B ^a   Pulitzer, Melissa P ^a   Berger, Michael F ^a   Scott, Sasinya N ^a   Iyriboz, Tunc ^a   Lacouture, Mario E ^a   Panageas, Katherine S ^a   Wolchok, Jedd D ^a,b   Carvajal, Richard D ^a   Schwartz, Gary K ^a   Rosen, Neal ^a   Chapman, Paul B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARRY 1428869; B RAF KINASE; SELUMETINIB; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTICLE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOWN REGULATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; ENZYME ACTIVATION; EXON; FATIGUE; FEMALE; GENE MUTATION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART RIGHT VENTRICLE FAILURE; HUMAN; HUMAN TISSUE; HYPOALBUMINEMIA; LIVER FUNCTION TEST; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MALE; MELANOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SIDE EFFECT; SIGNAL TRANSDUCTION; SURVIVAL RATE; THORAX PAIN; UPREGULATION; VALVULAR HEART DISEASE; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; BENZIMIDAZOLES; COHORT STUDIES; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; EXANTHEMA; FEMALE; HUMANS; LYMPHOPENIA; MALE; MELANOMA; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84877092892     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3476     Document Type: Article

References (28)

1. Davies H, Bignell G, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54. (Pubitemid 34716871)
2. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353:2135-47. (Pubitemid 41653105)
3. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19.
4. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
5. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707-14.
6. Jakob JA, Bassett RL Jr, Ng CS, Curry JL, Joseph RW, Alvarado GC, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012;118:4014-23.
7. Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, Taylor BS, et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A 2010;107:14903-8.
8. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006;439:358-62. (Pubitemid 43128863)
9. Gopal YN, Deng W, Woodman SE, Komurov K, Ram P, Smith PD, et al. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res 2010;70:8736-47.
10. Kirkwood JM, Bastholt L, Robert C, Sosman J, Larkin J, Hersey P, et al. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res 2012;18:555-67.
11. Wagle N, Berger MF, Davis MJ, Blumenstiel B, Defelice M, Pochanard P, et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov 2012;2:82-93.
12. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009;25:1754-60.
13. Braunschweig AB, Huo F, Mirkin CA. Molecular printing. Nat Chem 2009;1:353- 8.
14. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011;39:D945-50.
15. Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G, et al. Integrative genomics viewer. Nat Biotechnol 2011;29:24-6.
16. Emery CM, Vijayendran KG, ZipserMC, Sawyer AM, Niu L, Kim JJ, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A 2009;106:20411-6.
17. Sosman JA, Pavlick AC, Schuchter LM, Lewis KD, McArthur GA, Cowey CL, et al. PTEN immunohistochemical expression as part of the correlative analysis in the BRIM-2 trial. J Clin Oncol 30, 2012 (suppl; abstr 8503).
18. Nathanson KL, Martin AM, Letrero R, D'Andrea K, O'Day S, Infante JR, et al. Tumor genetic analysis of patients with metastatic melanoma treated with the BRAF inhibitor GSK2118436. J Clin Oncol 29:2011 (suppl; abstr 8501).
19. Xing F, Persaud Y, Pratilas CA, Taylor BS, Janakiraman M, She QB, et al. Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene 2012;31:446-57.
20. Cai CQ, Peng Y, Buckley MT, Wei J, Chen F, Liebes L, et al. Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations. Oncogene 2008;27:3201-10. (Pubitemid 351693177)
21. Tsao M-S, Sakurada A, Cutz J-C, Zhu C-Q, Kamel-Reid S, Squire J, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-44. (Pubitemid 41058345)
22. Murugan A, Dong J, Xie J, Xing M. Uncommon GNAQ, MMP8, AKT3, EGFR, and PIK3R1 mutations in thyroid cancers. Endocr Pathol 2011;22:97-102.
23. Douglas DA, Zhong H, Ro JY, Oddoux C, Berger AD, Pincus MR, et al. Novel mutations of epidermal growth factor receptor in localized prostate cancer. Front Biosci 2006;11:2518-25. (Pubitemid 43810020)
24. Pastorino L, Cusano R, Nasti S, Faravelli F, Forzano F, Baldo C, et al. Molecular characterization of Italian nevoid basal cell carcinoma syndrome patients. Hum Mutat 2005;25:322-3.
25. Patel SP, Lazar AJ, Papadopoulos NE, Liu P, Infante JR, Glass MR, et al. Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma. Cancer 2013;119:799-805.
26. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694-703.
27. Ascierto PA, Berking C, Agarwala S, Schadendorf D, Van Herpen C, Queirolo P, et al. Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastastic cutaneous melanoma harboring BRAFV600 or NRAS mutations. J Clin Oncol 30, 2012 (suppl; abstr 8511).
28. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, et al. A landscape of driver mutations in melanoma. Cell 2012;150:251-63.